Dr. DeAngelo on Inotuzumab Ozogamicin for Relapsed/Refractory ALL

Daniel J. DeAngelo, MD, PhD
Published: Tuesday, Jul 26, 2016


Daniel J. DeAngelo, MD, PhD, director of clinical and translational research, Adult Leukemia Institute (ALL), Dana-Farber Cancer Institute, discusses inotuzumab ozogamicin compared to standard chemotherapy in the INO-VATE study for patients with acute lymphoblastic leukemia (ALL).
 
Inotuzumab ozogamicin is an anti–CD22 antibody-drug conjugate. Over 90% of patients with B-cell ALL express CD-22 on their surface. Several phase I and II studies showed that inotuzumab ozogamicin had very high clinical activity/  
 
 In the phase III trial INO-VATE trial inotuzumab ozogamicin demonstrated a median PFS of 5.0 months (95% CI, 3.7-5.6) compared with 1.8 months (95% CI, 1.5-2.2) with standard chemotherapy (HR, 0.45; 97.5% CI, 0.34-0.61; P <.001)
 
The complete remission (CR) or CR with incomplete hematologic recovery (CRi) rate was 80.7% with inotuzumab ozogamicin (95% CI, 72.1-88.7) compared with 29.4% of those who received standard chemotherapy (95% CI, 21.0-38.8; P <.001).
 

Daniel J. DeAngelo, MD, PhD, director of clinical and translational research, Adult Leukemia Institute (ALL), Dana-Farber Cancer Institute, discusses inotuzumab ozogamicin compared to standard chemotherapy in the INO-VATE study for patients with acute lymphoblastic leukemia (ALL).
 
Inotuzumab ozogamicin is an anti–CD22 antibody-drug conjugate. Over 90% of patients with B-cell ALL express CD-22 on their surface. Several phase I and II studies showed that inotuzumab ozogamicin had very high clinical activity/  
 
 In the phase III trial INO-VATE trial inotuzumab ozogamicin demonstrated a median PFS of 5.0 months (95% CI, 3.7-5.6) compared with 1.8 months (95% CI, 1.5-2.2) with standard chemotherapy (HR, 0.45; 97.5% CI, 0.34-0.61; P <.001)
 
The complete remission (CR) or CR with incomplete hematologic recovery (CRi) rate was 80.7% with inotuzumab ozogamicin (95% CI, 72.1-88.7) compared with 29.4% of those who received standard chemotherapy (95% CI, 21.0-38.8; P <.001).
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x